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The hepatitis B virus (HBV) is estimated to chronically infect 350 
million people worldwide,1 of whom 65 million live on the African 
continent. Sub-Saharan Africa has a high endemicity, and more than 
50 million people are believed to be chronic carriers of the HBV.2 HBV 
is resistant to breakdown, can survive outside the body, and is easily 
transmitted through contact with infected body fluids.3 The prevalence 
of chronic hepatitis B infection varies greatly around the world and is 
closely associated with the main routes of HIV transmission.4 Modes 
of transmission of hepatitis B vary, since the virus is present in blood, 
saliva, semen, vaginal secretions, menstrual blood, and in smaller 
quantities in perspiration, breast milk, tears and urine of the infected 
individual. Worldwide, HBV is predominately transmitted perinatally.5,6 
Age at infection and risk of chronicity are inversely correlated;7,8 90% 
of infants born to a mother who is HbeAg-positive (core-associated 
antigen) will become lifelong HBV carriers6 whereas less than 5% 
of immunocompetent adults become carriers. Perinatally-acquired 
chronic hepatitis B infection is linked to cirrhosis, hepatic carcinoma, 
glomerulonephritis and end-stage renal disease in children.7,9
From women who are seropositive for both HBsAg (surface 
antigen) and HBeAg (core-associated antigen), vertical transmission 
approaches 90%.10 Universal maternal screening and newborn 
immunisation can drastically reduce perinatal transmission rates,6 
by vaccination of infants within 12 hours of birth with hepatitis B 
vaccine as well as with anti-viral therapy in late pregnancy.1,11 Use of 
only the hepatitis B vaccine to prevent vertical transmission has been 
supported in remote areas of the world.12,13 Given the impracticality of 
screening all pregnant women and the unavailability of the hepatitis 
B immune globulin (HBIG) in many developing countries, the use 
of the hepatitis B vaccine alone is recommended and considered 
appropriate treatment to prevent many cases of HBV during the 
perinatal period – the period of highest risk of chronicity.14
In 2008, the staff at the Hospital for Women and Children 
in Koutiala, Sikasso Region, south-eastern Mali, began screening 
pregnant women for hepatitis B and to immunise newborn infants 
born to women who tested positive for HBsAg. The prevalence rate 
data of HBsAg in Malian pregnant women in this paper are part of 
a larger ongoing hepatitis B prevention programme targeting infants 
for immunisation against hepatitis B on the first day of life.
Hepatitis B global infection rates published at www.pkids.org 
indicate that Mali has a 15.5% prevalence of HBV. The research 
literature in the last 10 years revealed few studies on the prevalence 
of hepatitis B in Mali in any population. A study of 11 592 blood 
donors in Bamako, Mali’s capital city, screened during 2001 and 
2002, revealed a prevalence of HBsAg of 14.9%.15 Another study of 
25 543 blood donors in 2007 revealed a slightly lower prevalence of 
13.9%.16 A screening of 152 medical students in Bamako revealed 
an HBsAg of 56%.17 Only one study of pregnant Malian women and 
HBV prevalence was found in the literature. Data for that study were 
gathered in the late 1990s from 829 pregnant women in Bamako and 
revealed that 15.5% had the serologic marker for the HBsAg.18 A 
recent HBV prevalence rate among pregnant women living outside 
Mali’s capital city is unavailable.
Methods
A descriptive comparative cross-sectional design guided this study. 
Ethical review and approval were received from the administration 
of the Koutiala Hospital for Women and Children and the Human 
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Objective. To establish the rate of seroprevalence of the hepatitis B 
surface antigen in pregnant women in south-eastern Mali, and to 
decrease mother-to-child transmission.
Methods. In a descriptive cross-sectional comparison study, 
3 659 pregnant women attending a non-governmental hospital 
in Koutiala, Mali, during 2008 and 2009 were screened for the 
hepatitis B surface antigen during antenatal clinic attendance or 
when admitted for delivery. A chart review compared the hepatitis 
B virus (HBV)-positive women to HBV-negative women used as 
controls to identify potential risk factors for HBsAg positivity. 
The variables compared were age, parity, type of genital excision, 
birthweight of baby and HIV status.
Results. A total of 293 (8.0%) pregnant women tested positive 
for HBsAg. Their average age was 27.6 years, average parity of 2.8 
births, 90% had Type 2 genital excision, 21% had low-birthweight 
infants, and 14 (0.4%) women also tested positive for HIV. Infants 
born to HbsAg-positive women were immunised with the hepatitis 
B vaccine in the delivery room. Two hundred and eighty-four HBV-
negative women were compared with the HBV-positive women. 
None of the differences of means or relationships was statistically 
insignificant.
Conclusion. In view of the high endemicity and lack of easily 
identifiable risk factors, free maternal HBV screening should be 
provided to all women in Mali, and the infants born to HBsAg-
positive women should be immunised within 12 hours of birth.
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Research Committee at Malone University, Canton, Ohio, USA. The 
importance of screening was explained to each woman at her first 
antenatal visit. HBV screening was explained to women who had 
not had antenatal visits at the hospital upon arrival at the maternity 
department for delivery. Consistent with Malian governmental 
guidelines, verbal consent was obtained before screening, and all 
results were kept confidential.
Women who came to antenatal clinic and consented to screening 
were directed to the hospital’s laboratory. Women who tested HBsAg-
positive during antenatal consultations were encouraged to return to 
the study-site hospital for delivery and immunisation of the newborn 
during its first hours of life. Women admitted to the hospital during 
labour without prior screening had their blood drawn in the delivery 
room after giving consent. SD BIO Standard Diagnostic India was 
used for the serum/plasma tests conducted in the laboratory, and 
Vikia Brasil Biomerieux was used for the serum/plasma/whole blood 
tests done in the delivery room.
Data collection and analysis
Data of women screened in 2008 and 2009 were included. A chart 
review of the women who were found to be HBsAg-positive was 
conducted and the following variables noted: age, parity, type of 
genital excision, birthweight of baby, and HIV status. Genital excision 
is noted as a potential risk factor for hepatitis B transmission.19,20 (A 
description of the types of genital excision can be found at the World 
Health Organization website.) HIV positivity – a noted risk factor for 
HBV infection – was only available for the HBV-positive women, and 
therefore a comparative analysis of the HIV variable was not done.
A comparison group of HBsAg-negative controls was included 
in the study by virtue of a random sample of charts of women who 
gave birth at the same hospital during the same years. To randomise 
the comparison sample, every 12th woman in the birth registry was 
chosen; if the randomly selected woman happened to be one who was 
HBsAg-positive, the chart of the next woman on the list was retained. 
SPSS version 18.0 was used for analysis of frequencies, means, chi-
squares, t-tests, and analysis of variance.
Results
From May 2008 to end December 2009, 3 659 pregnant women 
were screened for HBsAg; 293 (8.0%) tested positive; 14 (0.38%) 
HBsAg-positive women were co-infected with HIV. Table I illustrates 
frequencies of descriptive variables of the sample, comparing HBV-
positive and HBV-negative women. The women who screened 
positive for HBsAg were not demographically different from the 
HBsAg-negative women who gave birth during the same timeframe, 
and were randomly sampled from the birth registry. There was no 
statistically significant association between HBsAg positivity and 
the type of excision the woman had experienced (chi-square 5.233, 
df 3, p=0.155). The women who tested positive for HBsAg were 
almost the same mean age as the HBsAg-negative women (27.6 
and 25.9 respectively) and had only a slightly lower number of 
pregnancies (2.8 and 3.1 respectively). The differences of means and 
their statistical significance for age, parity, and birthweight of baby 
comparing HBV-positive with HBV-negative women are displayed in 
Table II. None of the differences of means was statistically significant.
Discussion
The seroprevalence level of HBsAg of 8.0% in this study of Malian 
pregnant women was lower than the 15.5% found among pregnant 
women in Bamako, Mali’s capital.18 The HBsAg positivity rate 
among pregnant women in Cote d’Ivoire was 8.5%, similar to Malian 
women;21 higher than pregnant women in Sierra Leone (6.2%);22 
and lower than pregnant women in Burkina Faso (17.3%)23 and 
Nigeria (11%).24 The Malian prevalence rate is also higher than that 
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Table I. Frequencies of descriptive variables comparing HBV-positive women (N=80*) with HBV-negative women (N=284)
HBV-positive women HBV-negative women
Variable N (%) N (%)
Age
   13 - 23
   24 - 34
   35 - 46
Mean (SD) 27.59 (6.6)
128 (45.7)
120 (42.9)
32 (11.4)
Mean (SD) 25.90 (7.2)
126 (44.4)
116 (40.8)
42 (14.8)
Parity Mean (SD) 2.81 (2.7) Mean (SD) 3.08 (2.7)
Babies' birth weights (g)*†
   501 - 1 000
   1 001 - 1 500
   1 501 - 2 000
   2 001 - 2 500
   2 501 - 3 000
   3 001 - 3 500
   3 501 - 4 000
   >4 000
Mean (SD) 2 851.71 (524.4)
3 (1.6)
2 (1.1)
3 (1.6)
31 (16.6)
74 (39.6)
60 (32.1)
14 (7.5)
0 (0.0)
Mean (SD) 2 898.53 (566.1)
3 (1.1)
5 (1.8)
13 (4.7)
26 (9.3)
102 (36.6)
101 (36.2)
28 (10.0)
1 (0.4)
Excision type‡
   Not excised
   Type 1
   Type 2
   Type 3
5 (3.3)
8 (5.3)
137 (90.1)
2 (1.3)
9 (3.8)
22 (9.3)
206 (86.9)
0 (0.0)
*During 2009, staff stopped recording babies weighing <500 g at birth in the same birth registry as births >500 g; therefore average birth weight was higher in 2009 than in 2008.
†Data of the women who tested positive for HBV during prenatal visits in 2009 but had not yet given birth at the time of data collection were not available to include in the analysis of birth weights.
‡N≠293 for HBV-positive women because of missing chart data.
of pregnant women in several East African countries: Sudan (5.6%),25 
Uganda (4.9%) and Rwanda (2.4%).26 Female excision did not emerge 
as a risk factor for hepatitis B infection in this sample, similar to 
findings in Tanzania19 and Nigeria.27
Since maternal screening and newborn immunisation are known 
to reduce perinatal transmission rates,6 immunisation of infants 
born to HBsAg-positive women at the Hospital for Women and 
Children in Koutiala began simultaneously with the HBV screening 
programme in 2008. Screening continues to be offered to all pregnant 
women, with the goal of preventing perinatal HBV transmission. 
The screening fee is included in the cost of antenatal care. All babies 
born to women who test positive for HBsAg are vaccinated within 12 
hours of birth, and this immunisation is noted in the hospital record. 
A large sign in the hospital’s labour room reminds obstetric staff to 
verify each woman’s HBsAg status and to give the hepatitis vaccine 
to the newborn when indicated. (HBIG is not readily available so 
it is not used in this prevention strategy per research evidence of 
sufficient coverage with HB vaccine alone.14,28) The infants who are 
immunised in the delivery room are subsequently tracked in the well-
baby clinic where completion of the immunisation series is promoted. 
These same infants return for free follow-up hepatitis B screening 
at 9 months of age. A register with contact information is kept to 
telephone mothers who fail to return.
In conclusion: the 8% hepatitis B prevalence rate found is this 
sample of pregnant Malian women indicates a high endemicity 
level of HBV and a clear danger of perinatal transmission. Free 
screening of pregnant women in Mali is strongly recommended to 
spare children from the hepatitis B virus and its chronic and fatal 
consequences.
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Table II. Differences of means and statistical significance of select variables for HBV-positive v. HBV-negative women
Variable HBV+ women HBV- women
ANOVA
F statistic p value
Age 25.79 (6.60) 25.90 (7.18) 0.037 0.848
Parity 2.81 (2.66) 3.08 (2.70) 1.429 0.233
Babies' birth weights (g) 2 851.71 (524.35) 2 898.53 (566.08) 0.812 0.368
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